# Variation in blood test monitoring practices for patients treated with conventional and biologic DMARDs

**Authors:** Joanne Ablewhite, Amy Fuller, Abdullah Almayahi, Abhishek Abhishek

PMC · DOI: 10.1093/rap/rkaf044 · Rheumatology Advances in Practice · 2025-04-16

## Full-text entities

- **Diseases:** arthritis (MESH:D001168), ulcerative colitis (MESH:D003093), inflammatory bowel disease (MESH:D015212), renal disease (MESH:D007674), inflammatory (MESH:D007249), RA (MESH:D001172), hepatic, haematological and renal adverse reactions (MESH:D065227), Crohn's & Colitis (MESH:D003424), Psoriasis (MESH:D011565), Ankylosing Spondylitis (MESH:D013167), toxicity (MESH:D064420), Lupus (MESH:D008180)
- **Chemicals:** leflunomide (MESH:D000077339), thiopurines (MESH:C520399), methotrexate (MESH:D008727), sulfasalazine (MESH:D012460), bDMARD (-), 5-aminosalicylic acid (MESH:D019804)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12077759/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12077759/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12077759/full.md

---
Source: https://tomesphere.com/paper/PMC12077759